DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ESTRACE

Summary for Tradename: ESTRACE

Patents:0
Applicants:2
NDAs:4
drug
patent expirations by year for
 ESTRACE

Clinical Trials for: ESTRACE

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
Status: Active, not recruiting Condition: Atrophic Vaginitis; Breast Cancer

Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Status: Completed Condition: Hot Flashes

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions
Status: Completed Condition: Healthy

Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function
Status: Completed Condition: Cardiovascular Diseases

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
Status: Completed Condition: Sexual Dysfunction, Physiological

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 Mcg and VagifemĀ® 10 Mcg and Compare to Placebo
Status: Completed Condition: Atrophic Vaginitis Due to Menopause

Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions
Status: Completed Condition: Healthy

Postpartum Depression: Transdermal Estradiol Versus Sertraline
Status: Terminated Condition: Postpartum Depression

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions
Status: Completed Condition: Healthy

Estradiol Levels in Patients Treated With Estring
Status: Recruiting Condition: Estrogen Levels Among Breast Cancer Patients

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
ESTRACE
estradiol
TABLET;ORAL081295Jun 30, 1993DISCNNo<disabled><disabled>
Bristol Myers Squibb
ESTRACE
estradiol
TABLET;ORAL084499Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
Bristol Myers Squibb
ESTRACE
estradiol
TABLET;ORAL084500Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
Warner Chilcott Us
ESTRACE
estradiol
CREAM;VAGINAL086069Jan 31, 1984RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc